mms prassad koppolu

In his role as Corporate Advisor, Prasad will continue to advise on strategic direction, and optimize growth and scale across all global locations.

Prasad has demonstrated a successful track record of senior leadership in complex, global, customer-focused organizations. He recognizes the strength and value that exceptional talent brings to our business and service functions while applying the best practices from ISO certifications and principles. He also leads infrastructure expansion, supporting the company’s projected growth and driving improved global connectivity.

Diversity is the most powerful force in the world. We all come from different backgrounds, and the differences that we have are used in a positive, unified way to assist sponsors in making the world a better place. Diversity of skills, talent, and experiences is our strength, and we are proud of it.
Prasad M. Koppolu
Corporate Advisor

Prasad has more than 25 years of experience across a diverse group of industries, including technology, transportation, energy, and professional services. He has held senior leadership positions in business development, operations, and research and development, among others.

Prasad earned his master’s degrees in industrial engineering and mechanical engineering from Clarkson University in New York and the Indian Institute of Technology.

Suggested For You

webinar

October 22nd, 2024

Optimal Strategies to Protect Commercially Confidential Information (CCI) in Clinical Documents and Report Trial Results Under Revised EU-CTIS Transparency Rules

perspectives

September 30th, 2024

Meet the Leaders Driving MMS’s European Growth

perspectives

September 30th, 2024

The Future of Data Management and Biostatistics: Trends and Technologies Shaping the Industry

perspectives

September 24th, 2024

Embracing Quality Management Maturity (QMM) at the Cornerstone of the Pharmaceutical Industry

perspectives

September 11th, 2024

From Historical Precedent to Modern Approvals: Lessons Learned on OTC Drug Products for FDA OMORs

webinar

September 26th, 2024

Regulatory Pathways for Nonprescription Drugs: A Deep Dive into OTC Monograph Reform and FDA Guidance

perspectives

September 4th, 2024

Email Security – Navigating Through the Process of Validation and Compliance with Healthcare Business Stakeholders

perspectives

August 27th, 2024

Optimizing Oncology Drug Development: FDA Expedited Pathways, Real-Time Review, and Global Programs

regulatory intelligence

August 27th, 2024

Recent Guidance on Diversity Action Planning

regulatory intelligence

August 26th, 2024

Oncology Programs at the FDA

regulatory intelligence

August 26th, 2024

Three Key Take Reflections on the Recent Donanemab Approval

perspectives

August 20th, 2024

Clinical Study Protocols: A Comprehensive Guide to Best Practices From A Senior Medical Writer